Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Linda, Mellbin"'
Autor:
Bashaaer Sharad, Nils Eckerdal, Martin Magnusson, Halldora Ögmundsdottir Michelsen, Amra Jujic, Matthias Lidin, Linda Mellbin, Nael Shaat, Ronnie Pingel, John Wallert, Emil Hagström, Margrét Leósdóttir
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background Despite the detrimental impact of abnormal glucose metabolism on cardiovascular prognosis after myocardial infarction (MI), diabetes is both underdiagnosed and undertreated. We investigated associations between structured diabetes
Externí odkaz:
https://doaj.org/article/f5e222a05f964888b24a31c0b88c4f93
Autor:
Lis Frykler Abazi, Andreas Liliequist, Felix Böhm, Magnus Hedberg, Moa Simonsson, Anders Bäckman, Malin Ax, Frieder Braunschweig, Linda Mellbin, Rickard Linder, Leif Svensson, Juliane Jurga, Per Nordberg, Mattias Ringh, Sune Forsberg, Jacob Hollenberg
Publikováno v:
Resuscitation Plus, Vol 18, Iss , Pp 100596- (2024)
Background: The aim of this study was to evaluate the implementation of a novel extra corporeal cardiopulmonary (ECPR) program in the greater Stockholm area with focus on feasibility, safety aspects and clinical outcomes. Methods: Prospective observa
Externí odkaz:
https://doaj.org/article/a4088e7a405345288db809d9a37bb762
Autor:
Alessia Riccio, Elena Fortin, Linda Mellbin, Anna Norhammar, Per Näsman, Lars Rydén, Giorgio Sesti, Giulia Ferrannini
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background Females are generally less prone to cardiovascular (CV) events than males, but this protection is trumped by diabetes. The mechanism behind the increased relative risk in females with diabetes is not fully understood. Insulin resi
Externí odkaz:
https://doaj.org/article/29b19a77abd648ce98b2f8cec2dd5c7e
Autor:
Elena Fortin, Magnus Lundin, Linda Mellbin, Anna Norhammar, Per Näsman, Stina Smetana, Peder Sörensson, Ele Ferrannini, Lars Rydén, Giulia Ferrannini
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-11 (2023)
Abstract Background Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such benefit have not been f
Externí odkaz:
https://doaj.org/article/bc8090c54dee4cd4b7a30993c322c26d
Autor:
Elena Fortin, Giulia Ferrannini, Beatrice Campi, Linda Mellbin, Anna Norhammar, Per Näsman, Alessandro Saba, Ele Ferrannini, Lars Rydén
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-10 (2022)
Abstract Background Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial infarction (MI) across d
Externí odkaz:
https://doaj.org/article/b3c4383134694b8aab15410f8476283f
Autor:
Eline Wu, Ali Mahdi, Jannike Nickander, Judith Bruchfeld, Linda Mellbin, Kristina Haugaa, Marcus Ståhlberg, Liyew Desta
Publikováno v:
Cardiology Research and Practice, Vol 2023 (2023)
Background. Postacute sequelae of SARS-CoV-2 infection (PASC) are a novel clinical syndrome characterized in part by endothelial dysfunction. Enhanced external counterpulsation (EECP) produces pulsatile shear stress, which has been associated with im
Externí odkaz:
https://doaj.org/article/32fd55f6b5d94115a0293a9d4816dc9e
Autor:
Giulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, Guy De Backer, Viveca Gyberg, Kornelia Kotseva, Linda Mellbin, Anna Norhammar, Jaakko Tuomilehto, David Wood, Lars Rydén, EUROASPIRE IV & V Investigators
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Background Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data from two nationwide
Externí odkaz:
https://doaj.org/article/0348029b0ef54ed2ab14d6064ea94aad
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Introduction Cardiovascular (CV) effects of once‐weekly subcutaneous (s.c.) semaglutide 0.5 and 1 mg and dulaglutide 1.5 mg are reported in their respective placebo‐controlled cardiovascular outcome trials (CVOTs), SUSTAIN 6 and REWIND.
Externí odkaz:
https://doaj.org/article/b62f1c426cd5413bae6fb71293e4bcd7
Autor:
Kathleen M. Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C. Woo, Tina Vilsbøll
Publikováno v:
Diabetes Therapy.
Introduction A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide ve
Autor:
TONJE Thorvaldsen, GIULIA FERRANNINI, LINDA MELLBIN, LINA BENSON, FRANCESCO COSENTINO, JOHN J.V. MCMURRAY, ULF DAHLSTRÖM, LARS H. LUND, GIANLUIGI SAVARESE
Publikováno v:
Journal of Cardiac Failure. 28:1050-1062
Background: We investigated eligibility for dapagliflozin and empagliflozin in a real-world heart failure (HF) cohort based on selection criteria of DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), DELIVER (Dapagliflozin E